Healthcare · Profile from Healthcare Research Companion
Pfizer Inc.
The Brooklyn chemicals firm that became the archetype of the big-pharma acquirer. Pfizer bought its way to the top of the industry with Warner-Lambert (for Lipitor), Pharmacia and Wyeth, survived the Lipitor patent cliff, failed twice to buy its way into a lower tax bill, then earned the largest one-off windfall in the industry's history with the BioNTech Covid-19 vaccine and Paxlovid. Since 2023 it has spent that windfall on Seagen and obesity bets while revenue fell back toward pre-pandemic levels, and in 2025 it became the first drugmaker to sign a "most-favored-nation" pricing deal with the White House.
At a glance
- Founded
- 1849, Brooklyn, New York, as Charles Pfizer & Company (fine chemicals: santonin, then citric acid)
- Founders
- Cousins Charles Pfizer (chemist) and Charles Erhart (confectioner), German immigrants from Ludwigsburg
- Headquarters
- New York City (The Spiral, Hudson Yards, since 2023); major R&D in Groton (Connecticut), Cambridge (Massachusetts), Pearl River (New York) and Bothell (Washington, ex-Seagen)
- Ownership / structure
- Public company, NYSE: PFE; widely held, no controlling shareholder
- Leadership (2026)
- Albert Bourla, Chairman and CEO (CEO since January 2019); Cecile Guegan, Interim CFO (from 16 August 2026, after David Denton left; permanent search under way); Chris Boshoff, Chief Scientific Officer and President, R&D (since January 2025)
- Segments
- Biopharma: primary care (Eliquis with Bristol Myers Squibb, vaccines incl. Prevnar 20 and Abrysvo, Comirnaty, Paxlovid), specialty care (Vyndaqel family, inflammation, hospital products) and oncology (Ibrance, Xtandi, Padcev, Adcetris, Lorbrena); Pfizer Ignite and contract manufacturing are small
- Payer and patient
- Commercial plans and PBMs, Medicare Part D and Part B, Medicaid, governments (vaccines, pandemic purchases) and, since 2024–26, cash-pay patients via PfizerForAll and TrumpRx (reported)
- Scale
- 2025 revenue $62.6bn (reported; down 2% operationally; +6% excluding Comirnaty and Paxlovid); ~75,000 employees (end-2025, down from ~81,000, reported); 2026 revenue guidance $59.5–62.5bn, raised to $60.5–62.5bn (4 August 2026)
- Capital / market cap
- Self-funded through operations and debt; ~$31bn of new debt for Seagen (2023). Market cap peaked ~$300bn+ (December 2021) and was roughly ~$140–160bn in 2025–26 (share price ~$23–28)
- Signature moves (incl. failures)
- Lipitor and the hostile Warner-Lambert takeover (2000); Wyeth (2009); record $2.3bn Bextra off-label settlement (2009); Lipitor patent cliff (2011); failed AstraZeneca bid (2014) and abandoned Allergan inversion (2016); Comirnaty and Paxlovid (2020–22) and the post-Covid revenue collapse; Seagen (2023); first MFN pricing deal and the Metsera bidding war with Novo Nordisk (2025)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2000
Warner Lambert and Lipitor
Acquisition (hostile, after a co-promotion partnership)
2009
Bextra Off Label Settlement
Regulatory settlement (criminal plea and civil False Claims Act settlement)
2009
Wyeth Acquisition
Acquisition
2011
Lipitor Patent Cliff
Loss of exclusivity / pricing change (defensive commercial strategy)
2016
Allergan Inversion Abandoned
Merger (failed); preceded by a rejected bid for AstraZeneca (2014)
2020
Covid Vaccine and Paxlovid
Partnership / launch (followed by a revenue collapse)
2023
Seagen Acquisition
Acquisition
2025
MFN Deal and Metsera
Pricing change (government pricing agreement) and acquisition